請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24839
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 余榮熾(Lung-Chih Yu) | |
dc.contributor.author | Yuh-Ching Twu | en |
dc.contributor.author | 涂玉青 | zh_TW |
dc.date.accessioned | 2021-06-08T05:57:07Z | - |
dc.date.copyright | 2008-01-17 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-01-14 | |
dc.identifier.citation | Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K.
Current Protocols in Molecular Biology. John Wiley & Sons; 1996. Bierhuizen MFA, Mattei M-G, Fukuda M. Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family. Genes Dev. 1993;7:468-478. Birkemeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, Landschulz WH, McKnight SL. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev. 1989;3:1146- 1156. Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer SD. Induction of C/EBPα activity alters gene expression and differentiation of human CD34+ cells. Blood. 2003;101:2206-2214. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 1991;5:1538-1552. Chen G-Y, Muramatsu H, Kondo M, Kurosawa N, Miyake Y, Takeda N, Muramatsu T. Abnormalities caused by carbohydrate alternations in I β6-N-acetylglucosaminyltransferase- deficient mice. Mol Cell Biol. 2005;25:7828-7838. Chen JY, Ling UP. Prediction of the development of neonatal hyperbilirubinemia in ABO incompatibility. Zhonghua Yi Xue Za Zhi (Taipei). 1994;53:13-18. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigentic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-Ia cells. J Immunol. 1984; 133:157-165. Clausen H, Hakomori S. ABH and related histo-blood group antigens: immunochemical differences in carrier isotype and their distribution. Vox Sang. 1989;56:1-20. Daniels G. Human Blood Groups. Oxford, England: Blackwell Sciences; 2002. Dzierzkowa-Borodej W, Osinska M. Anti-I antibodies in human milk. Arch Immunol Ther Exp. 1971;19:609-612. Feizi T, Kabat EA, Vicari G, Anderson B, Marsh WL. Immunochemical studies on blood groups. XLIX. The I antigen complex: specificity differences among anti-I sera revealed by quantitative precipitin studies; partial structure of the I determinant specific for one anti-I serum. J Immunol. 1971a;106:1578-1592. Feizi T, Kabat EA, Vicari G, Anderson B, Marsh WL. Immunochemical studies on blood groups. XLVII. The I antigen complex-precursors in A, AB, H, Lea and Leb blood group system-hemaagglutination-inhibition studies. J Exp Med. 1971b;133:39-52. Feizi T, Kabat EA. Immunochemical studies on blood groups. LIV. classification of anti-I and anti-i sera into groups based on reactivity patterns with various antigens 54 related to the blood group A, B, H, Lea, Leb and precursor substances. J Exp Med. 1972;135:1247-1258. Fukuda M, Fukuda MN, Hakomori S-I. Developmental change and genetic defect in the carbohydrate structure of band 3 glycoprotein of human erythrocyte membrane. J Biol Chem. 1979;254:3700-3703. Hirohashi S, Clausen H, Nudelman E, Inoue H, Shimosato Y, Hakomori S. A human monoclonal antibody directed to blood group i antigen: heterohybridoma between human lymphocytes from regional lymph nodes of a lung cancer patient and mouse myeloma. J Immunol. 1986;136:4163-4168. Hornick CL, Karush F. Antibody affinity-III. The role of multivalence. Immunochemistry. 1972;9:325-340. Inaba N, Hiruma T, Togayachi A, Iwasaki H, Wang XH, Furukawa Y, Sumi R, Kudo T, Fujimura K, Iwai T, Gotoh M, Nakamura M, Narimatsu H. A novel I-branching β-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood. 2003;101:2870-2876. Kannagi R, Papayannopoulou T, Nakamoto B, Cochran NA, Yokochi T, Stamatoyannopoulos G, Hakomori S-I. Carbohydrate antigen profiles of human erythroleukemia cell lines HEL and K562. Blood. 1983;62:1230-1241. Kim J, Cantwell CA, Johnson PF, Pfarr CM, Williams SC. Transcriptional activity of CCAAT/enhancer binding protein is controlled by a conserved inhibitory domain that is a target for sumoylation. J Biol Chem. 2002;277:38037-38044. Klinman NR, Karush F. Equine anti-hapten antibody. V. The non-precipitability of bivalent antibody. Immunochemistry. 1967;4:387-405. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood-derived stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood. 1986;67:529-532. Kozak M. An analysis of 5’-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987;15:8125-8148. Kozak M.Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes. Proc Natl Acad Sci USA. 1990;87:8301-8305. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev. 1988;2:786-800. Landschultz WH, Johnson PF, McKnight SL. The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite. Science. 1989;243:1681-1688. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer binding protein family of transcription factors. J Biol Chem. 1998;273:28545-28548. Lin-Chu M, Broadberry RE, Okubo Y, Tanaka M. The i phenotype and congenital cataract among Chinese in Taiwan. Transfusion. 1991;31:676-677. Lincoln AJ, Monczak Y, Williams SC, Johnson PF. Inhibition of CCAAT/enhancer55 binding protein α and β translation by upstream open reading frames. J Biol Chem. 1998;273:9552-9560. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. I. Normal erythroid development. Blood. 1987;69:255-263. Mahoney CW, Shuman J, McKnight SL, Chen HC, Huang KP. Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding. J Biol Chem. 1992;267:19396-19403. Marsh WL, Jenkins WJ. Anti-i: A new cold antibody. Nature. 1960;188:753. Marsh WL. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haematol. 1961;7:200-209. Marsh WL, Nichol ME, Allen FH. Inhibition of anti-I sera by human milk. Vox Sang. 1970;18:149-154. Marsh WL, Nichol ME, Reid ME. The definition of two I antigen components. Vox Sang. 1971;20:209-217. McKnight SL, Lane MD, Gluecksohn-Waelsch S. Is CCAAT/enhancer binding protein a central regulator of energy metabolism? Genes Dev. 1989;3:2021-2024. Niemann H, Watanabe K, Hakomori S, Childs RA, Feizi T. Blood group i and I avtivities of “lacto-N-norhexaosylceramide” and its analogues: the structural requirements for i-specificity. Biochem Biophys Res Commun. 1979;81:1286- 1293. Okubo Y, Yamaguchi H. I-negative phenotype and cataract. 19th Congr Int Soc Blood Transfus. 1986:147. Orkin SH, Swan D, Leder P. Differential expression of α- and β-globin genes during differentiation of cultured erythroleukemic cells. J Biol Chem. 1975;250:8753- 8760. Piller F, Cartron J-P, Maranduba A. Veyrieres A, Leroy Y, Fournet B. Biosynthesis of blood group I antigens. Identification of a UDP-GlcNAc:GlcNAcβ1-3Gal(-R) β1-6(GlcNAc to Gal) N-acetylglucosaminyltransferase in hog gastric mucosa. J Biol Chem. 1984;259:13385-13390. Porrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. BCR-ABL suppresses C/EBP α expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30:48-58. Radomask HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/ enhancer binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998;18:4301-4314. Rehemtulla A, Arndt A, Hart DA. Induction of plasminogen activator inhibitor type 2 expression during differentiation of human K562 cells towards a macrophage 56 phenotype. Biochem Cell Biol. 1990;68:1337-1343. Reid ME, Lomas-Francis C. The Blood Group Antigen Facts Book. San Diego, CA: Academic Press; 1997. Romanas DG, Tilley CA, Dorrington KJ. Monogamous bivalency of IgG antibodies. I. Deficiency of branched ABHI-active oligosaccharide chains on red cells of infants cause the weak antiglobulin reactions in hemolytic disease of the newborn due to ABO incompatibility. J Immunol. 1980;124:2807-2811. Rosenfield RE. A-B hemolytic disease of the newborn. Analysis of 1480 cord blood specimens, with special reference to the direct antiglobulin test and to the group O mother. Blood. 1955;10:17-28. Ross SE, Radomska HS, Wu B, Zhang P, Winnay JN, Bajnok L, Wright WS, Schaufele F, Tenen DG, MacDougald OA. Phosphorylation of C/EBPα inhibits granulopoiesis. Mol Cell Biol. 2004;24:675-686. Rouger P, Juszczak G, Doinel C, Salmon C. Relationship between I and H antigens, I. A study of the plasma and saliva of a normal population. Transfusion. 1980;20: 536-539. Schwientek T, Nomoto M, Levery SB, Merkx G, van Kessel AG, Bennett EP, Hollongsworth MA, Clausen H. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel β-1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. J. Biol. Chem. 1999;274:4504- 4512. Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood. 1992;80:1725-1735. Subramanian L, Benson MD, Iniguez-Lluhi JA. A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein α inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J Biol Chem. 2003;278:9134–9141. Suh HC, Gooya J, Renn K, Friedman AD, Johnson PF, Keller JR. C/EBPα determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation. Blood. 2006;107:4308-4316. Sutherland JA, Turner AR, Mannoni P, McGann LE, Turc JM. Differentiation of K562 leukemia cells along erythroid, macrophage, and megakaryocyte lineages. J Biol Response Modifiers. 1986;5:250-262. Teata U, Rochant H, Henri A. Change in i-antigen expression of erythrocytes during in vivo aging. Rev Franc Transfus Immuno Hemat. 1981;24:299-305. Testa U, Henri A, Bettaieb A, Titeux M, Vainchenker W, Tonthat H, Docklear MC, Rochant H. Regulation of i- and I-antigen expression in the K562 cell line. Cancer Res. 1982;42:4694-4700. Umek RM, Friedman AD, McKnight SL. CCAAT/enhancer binding protein: a 57 component of a differentiation switch. Science. 1991;251:288-292. Van Epps DE, Bender J, Lee W, Schilling M, Smith A, Smith S, Unverzagt K, Law P, Burgess J. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood. Blood cells. 1994;20:411-423. Wang GL, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBPα growth inhibitory activity. Genes Dev. 2004;18:912-923. Watanabe K, Hakomori S, Childs RA, Feizi T. Characterization of a blood group I-active ganglioside. J Biol Chem. 1979;254:3221-3228. Wiener AS, Unger LJ, Cohen L, Feldman J. Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: biologic test with bovine red cells. Ann Intern Med. 1956;44:221-240. Yamaguchi H, Okubo Y, Tanaka M. A note on possible close linkage between the Ii blood locus and a congenital cataract locus. Jpn Acad. 1972;48:625-628. Yeh JC, Ong E, Fukuda M. Molecular cloning and expression of a novel β-1,6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. J Biol Chem. 1999; 254:3221-3228. Yu LC, Twu YC, Chou ML, Reid ME, Gray AR, Moulds JM, Chang CY, Lin M. The molecular genetic of the human I locus and molecular background explain the partial association of the adult i phenotype with congenital cataracts. Blood. 2003;101:2081-2088. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24839 | - |
dc.description.abstract | 人類紅血球組織抗原I 和i 為以N-acetyllactosamine(Galβ1-4GlcNAc,LacNAc)
為單位,重複連結所形成的醣抗原結構。兩者的不同在於,i 抗原為直鏈形的醣結 構,而I 為具有β1-6 GlcNAc 分支的醣抗原結構。胎兒的紅血球表面表現大量的直 鏈形i 抗原,僅有少數的I 分支結構。過去的研究證實,胎兒於出生前其紅血球表 面持續保持i 抗原結構,不生成大量的I 分支,為保護胎兒不因與母體ABO 血型 不合而引發溶血症的重要機制之ㄧ。然而新生兒出生後,紅血球表面的i 抗原即逐 漸轉換成分支結構的I 抗原;此表現的調控機制至今仍不清楚。I 醣抗原形成的決 定酵素為I 基因座所表現的I β-1,6-N-acetylglucosaminyltransferase(IGnT),此酵 素可將直鏈形結構i 抗原轉換成分支的I 抗原結構。經由轉錄以及splicing 作用後, I 基因座會表現IGnTA、IGnTB 和IGnTC 三種transcripts;其蛋白質產物皆具有形 成I 分支結構的酵素活性。我們過去的研究已證明,紅血球表面I 抗原的生成是由 I 基因座的IGnTC 基因負責。 本論文選用erythroleukemia 細胞株K-562 做為紅血球分化模型,以探討調控I 抗原表現的分子機制。我們的研究證實,以sodium butyrate 誘發K-562 細胞進行 紅血球分化過程中,轉錄因子CCAAT/enhancer binding protein α(C/EBPα)透過調 控IGnTC 基因的表現,促使細胞表面I 抗原的生成。後續染色體免疫分析法以及 免疫沉澱法的結果顯示,C/EBPα 磷酸化狀態的改變可能影響其與IGnTC 基因轉錄 調控區域的結合能力,進而調控IGnTC 基因的表現。我們進一步以成人和胎兒 CD34+血球幹細胞為模型,藉由體內自然分化以及體外培養誘發紅血球分化過程, 以驗證紅血球表面I 抗原表現的調控機制;並以lentiviral 表現系統將C/EBPα 轉錄 因子表現於成人及胎兒CD34+細胞中;結果顯示,其調控機制亦如同K-562 細胞 分化模型所顯現,C/EBPα 為紅血球分化過程中調控I 抗原表現的決定因子。而實 驗結果皆顯示,調控C/EBPα 的後轉譯修飾作用的機制才可能是調控IGnTC 基因 表現,進行促成紅血球表面I 抗形成的機制。然而C/EBPα 於紅血球分化過程中的 iii 後轉譯修飾及其形成機制,以及此機制在成人和胎兒之間可能的異同,有待進一 步研究;釐清此機制,才可進一步回答胎兒紅血球表面保持直鏈的i 醣結構,而在 出生後,轉換成I 醣分支結構的詳盡機轉。 | zh_TW |
dc.description.abstract | The human histo-blood group I and i antigens are characterized as branched and
straight chains of N-acetyllactosamine (Galβ1-4GlcNAc, LacNAc) repeat, respectively. Fetal and neonatal erythrocytes predominantly express i antigen, with only a small amount of I. It has been recognized that the presence of the straight-chain i antigen on fetal erythrocytes surface is one of the important mechanisms to prevent the hemolytic disease due to ABO incompatibility pregnancy. After birth, the i antigen of erythrocyte is gradually converted to the branched I antigen; however, the regulatory mechanism for the I branching formation awaits elucidation. Conversion of the straight-chain i to the branched I antigen is catalyzed by the enzyme encoded by the I locus, I-branching β-1,6-N-acetylglucosaminyltransferase (IGnT). The human I locus expresses three IGnT transcripts, IGnTA, IGnTB, and IGnTC, which have different exon 1, but identical exon 2 and exon 3 regions. In our previous study, we have demonstrated that IGnTC is the intrinsic gene responsible for the I antigen expression on erythrocytes. In this thesis, the erythroleukemia cell line K-562 was used as a model to study the regulatory mechanism of I antigen expression during erythroid differentiation. Our results demonstrated that the transcription factor CCAAT/enhancer binding protein α (C/EBPα) stimulated the expression of IGnTC gene in sodium butyrate-induced erythroid differentiation of K-562 cells, and consequently enhanced the I antigen expression on the cell surfaces. The results obtained from chromatin immunoprecipitation (ChIP) and immunoprecipitation (IP) analysis, suggested that the phosphorylation status of C/EBPα may affect its binding affinity onto the 5’ regulatory region of IGnTC gene and thus regulates the expression of IGnTC gene. Human adult and cord CD34+ hemopoietic stem cells were employed to further investigate the role of C/EBPα in the I antigen expression during erythroid differentiation, and lentiviral expression system was used to introduce C/EBPα into adult and cord CD34+ cells. The v results demonstrated that the transcription factor C/EBPα played the determining role in the regulation of the I antigen expression during erythropoiesis. Furthermore, the results suggested that the function of C/EBPα in the IGnTC gene expression and the subsequent I antigen formation may be determined by the post-translational modification status of C/EBPα. The post-translational modification and the mechanism leading to this modification on C/EBPα during erythroid differentiation await further investigation, and it is of significance to further reveal the possible difference of this mechanism between adult and fetal erythropoiesis processes. Only after the elucidation these mechanisms of the post-translational modification on C/EBPα the mechanisms leading to the predominant expression of straight-chain i antigen on fetal erythrocytes and the i-to-I conversion after birth could be answered in more detail. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:57:07Z (GMT). No. of bitstreams: 1 ntu-97-D92B46003-1.pdf: 1165127 bytes, checksum: e061c9a067032513bbecc618ebe3fc9e (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 目錄
口試委員審定書⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ i 中文摘要⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅iii 英文摘要⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅v 縮寫表⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ x 第一章 緒論⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 1 一 人類紅血球組織抗原I 及i(Human histo-blood group I and i antigens)⋅⋅⋅⋅ 1 二 I 基因座(I locus)⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 2 三 Ii 抗原結構和母子ABO 血型不合導致的胎兒新生兒溶血症的關聯⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 3 四 研究構想與目的⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 4 第二章 材料與方法⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 7 一 細胞培養及分化⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 7 二 流式細胞儀之分析⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 8 三 RNA 萃取及同步定量Reverse Transcription-Polymerase Chain Reaction (Real-time RT-PCR)⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 8 四 報導基因分析法(Reporter assay)⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 9 五 蛋白質表現系統⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 11 六 細胞質蛋白和細胞核蛋白的萃取和西方點墨法(Western blot)⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 12 七 免疫沉澱法(Immunoprecipitation)⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 13 八 染色體免疫沉澱分析法(Chromatin immunoprecipitation;ChIP)⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 13 第三章 結果⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 17 一 K-562 細胞紅血球分化模型-I 抗原和IGnT 基因的表現⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 17 二 IGnTC 基因的5'端轉錄調控區域轉錄活性分析⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 18 三 轉錄因子C/EBPα對I 抗原和IGnT 基因表現的影響⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 19 四 C/EBPα與IGnTC 基因轉錄調控區域的結合⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 21 五 C/EBPα於K-562 細胞的後轉譯修飾(Post-translational modification)⋅⋅⋅⋅⋅⋅ 22 viii 六 成人及胎兒CD34+細胞和CD71+細胞的分離與紅血球分化⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 23 七 成人及胎兒紅血球分化過程I 抗原和IGnT 基因的表現⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 24 八C/EBPα在成人及胎兒紅血球分化過程I 抗原表現的作用⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 25 九 成人以及胎兒紅血球分化過程C/EBPα與IGnTC 基因轉錄調控區域的結 合⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 26 第四章 討論⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 29 參考文獻⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 53 圖目錄 圖1. Sodium butyrate 對K-562 細胞紅血球分化的影響⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 34 圖2. 紅血球分化過程I 抗原和IGnT 基因表現的變化⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 35 圖3. IGnTC 基因5’端轉錄調控區的分析⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 37 圖4. 轉錄因子對I 抗原和IGnT 基因表現的影響⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 39 圖5. 轉錄因子與IGnTC基因轉錄調控區域的結合⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 41 圖6. K-562 細胞紅血球分化過程C/EBPα的表現以及後轉譯修飾的變化⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 42 圖7. CD34+細胞、CD71+細胞和E-cultured 細胞的分離與分化⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 44 圖8. 成人及胎兒紅血球分化過程I 抗原和IGnT 基因的表現⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 45 圖9. 成人及胎兒紅血球分化過程C/EBPα的表現⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 47 圖10. 表現C/EBPα對成人及胎兒CD34+細胞I 抗原和IGnT 基因表現的影響⋅⋅⋅⋅⋅⋅⋅ 49 圖11. 成人及胎兒紅血球細胞分化過程C/EBPα與IGnTC基因轉錄調控區域的結合 ⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 51 附圖一 I 醣抗原的結構以及生合成路徑⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 58 附圖二 I 基因座以及IGnT 基因transcripts 的結構⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 59 附圖三 紅血球A和B抗原的結構以及合成路徑⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅⋅ 60 | |
dc.language.iso | zh-TW | |
dc.title | 紅血球分化過程I醣分支結構形成的調控機制 | zh_TW |
dc.title | Regulation of I Branching Formation in Erythroid Differentiation | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳義雄(Yee-Hsiung Chen),黃銓珍(Chang-Jen Huang),陳宏文(Hung-Wen Chen),邱繼輝(Kay-Hooi Khoo),張?仁(Ching-Jin Chang) | |
dc.subject.keyword | I醣抗原,紅血球分化, | zh_TW |
dc.subject.keyword | I antigen,erythroid differentiation, | en |
dc.relation.page | 56 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-01-14 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 1.14 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。